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response measure at 6 mos was predictive of subsequent OS
(p ¼ 0.007) and FFS (p¼0.004). Patient-reported changes
were associated with FFS after 3 mos but not with other
outcomes. No response measures predicted NRM. The fact
that FFS could be predicted by clinician- or patient-reported
response measures might reﬂect that clinicians and patients
control the main determinant of FFS, i.e., whether new sys-
temic immunosuppression is added. Incorporation of the
calculated CR + PR category did not signiﬁcantly change the
ability of the clinician-reported CR + PR to predict FFS or
survival after 6 months. We conclude that clinician-reported
CR+PR is highly associated with OS after 6 months, which is
independent of calculated CR+PR. Calculated response algo-
rithms might be improved by understanding and incorpo-
rating clinician judgment in assessing response.44
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Invariant natural killer T (iNKT) cells are potent regulators
of immune responses in humans (TCRa Va24-Ja18) and mice
(TCRa Va14-Ja18). We showed previously that host and
donor iNKT cells play a critical role for graft-versus-host
disease (GVHD) prevention and tolerance induction
following allogeneic hematopoietic cell transplantation
(HCT). In this study, we explored the role of adoptively
transferred third party CD4+ iNKT cells in a murine model of
allogeneic HCT across major histocompatibility barriers.
After 8 Gy total body irradiation BALB/c (H-2Kd) recipient
mice were transplanted with T cell-depleted bone marrowFigure 1. Representative bioluminescence images of BALB/c mice that
received Tcon alone or Tcon together with adoptively transferred third party
CD4+ iNKT cells. Tcon derived from FoxP3DTR/GFP/luc C57BL/6 mice with the
expression of the luciferase gene being under the control of the FoxP3
promoter.together with 1x106 CD4+/CD8+ T cells (Tcon) from C57BL/6
(H-2Kb) donor mice. Adoptive transfer of sorted (purity
>95%) 5x104 CD4+ iNKT cells from FVB/N (H2-Kq) third party
mice signiﬁcantly improved survival (p<0.001) while
retaining Tcon mediated graft-versus-tumor (GVT) effects
against BCL1 and A20 lymphoma cells (p¼0.002). Notably,
CD4+ iNKT cells from third party mice were as protective as
CD4+ iNKT cells from donor mice (p¼0.50). Consistently,
weight and GVHD scores improved in mice that received a
single injection of third party CD4+ iNKT cells as compared to
animals that received Tcon alone. Bioluminescence from
expanding luciferase expressing alloreactive Tcon was
signiﬁcantly decreased while showing a Th2-biased cytokine
proﬁle in animals treated with third party CD4+ iNKT cells
(p¼0.003). Interestingly, inhibition of Tcon proliferation
was comparable to animals that received CD4+ iNKT cells
from donor mice (p¼0.90). Although we found that third
party CD4+ iNKT cells were rejected by day +10 after allo-
geneic HCT, adoptive transfer resulted in a robust expan-
sion of luciferase expressing donor Treg using C57BL/6
FoxP3DTR/GFP/luc mice as a source of Tcon (p¼0.006, Figure 1).
Depletion of Treg from the graft by injection of diphtheria
toxin abrogated both donor Treg expansion and protection
from GVHD lethality through third party CD4+ iNKT cells. In
conclusion, low numbers of puriﬁed and adoptively trans-
ferred thirdparty CD4+ iNKTcells protect fromGVHD lethality
through activation and expansion of donor Tregwith retained
GVT effects. Despite the fact that iNKT cells are a rare cell
population, the in vivo activity of small numbers of cells and
feasibility of in vitro expansion provide the basis for clinical
translation.45
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Members of the sialic acid binding Igelike lectin (Siglec)
family, such as Siglec-G, have immunoreceptor tyrosine-
based inhibitory motifs (ITIM) regions that negatively
regulate innate immune activation induced by non-
infectious damage-associated molecular patterns (DAMPs).
The T-cell autonomous role of Siglec-G in modulating
immunity is not known. In order to examine the role of
Siglec-G on T cells we utilized the well-established MHC
disparate B6->BALB/c model of allogeneic BMT. BALB/c WT
mice were lethally irradiated (850cGy) and transplanted
on day 0 with 5x106 WT bone marrow from either
syngeneic WT-BALB/c or allogeneic WT-B6 along with
0.5x106CD90+T cells from WT or Siglec-G-/- B6 animals. The
allogeneic recipients receiving donor T cells from Siglec-G-/-
animals showed signiﬁcantly more severe GVHD and worse
survival compared to allogeneic WT-B6 animals (p¼0.01).
This increased mortality was also associated with greater
Figure. Change in individual and mean percentage FEV1% over time.
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such as HMGB1. Donor T cell analyses demonstrated
signiﬁcantly greater expansion of activated CD69+, Th1
(IFN-g+) and Th17 (IL-17A+) cells in the spleen and in the
GVHD target organs, namely liver and gut (P<0.05).
Enhanced GVHD mortality and severity was observed in
multiple irradiated BMT models (MHC-matched multiple
minor antigen mismatched C3H.sw->B6 and haploidentical
B6->F1 models). We performed detailed phenotypic analysis
of various T cell subsets in naïve Siglec-G-/- and WT B6
animals and found similar distribution of naïve, memory,
effector and regulatory T cells suggesting that alteration in
T-cell subsets in the donor T-cell inoculumwas not the cause
for increase in GVHD. Functional analyses of naïve Siglec-G-/-
T cells, showed similar proliferation in vitro after stimulation
with allogeneic DCs or CD3/CD28 antibody stimulationwhen
compared toWT Tcells. Furthermore Siglec-G-/- Tregs as well
as WT Tregs were equally suppressive in repressing either
WT or Siglec-G-/- naïve T-cells demonstrating that Siglec-G
expression on Tregs is not critical for their suppressive
function or on naïve T-cells to be regulated by Tregs. By
contrast Siglec-G-/- T cells showed higher proliferation after
TCR stimulation (CD3/CD28) only upon with addition of
DAMP (HMGB-1) demonstrating that direct regulation of
T-cell response to DAMP by Siglec-G regulates its TCR driven
proliferative responses. Finally, in order to explore the
Siglec-G+T cells interaction with its ligand in hosts, we next
used CD24-/- BALB/c animals as hosts. CD24-/- animals also
demonstrated enhanced GVHD mortality when compared to
WT animals. Collectively, our data suggest, for the ﬁrst time
to our knowledge that Siglec-G mediated responses to
DAMPs has T-cell autonomous effects and through its
engagement with its ligand CD24 in the hosts is critical for
mitigating GVHD.46
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Tokyo, JapanBackground: Bronchiolitis obliterans syndrome (BOS) after
allogeneic hematopoietic cell transplant (HCT) is associated
with high mortality. Recently, we showed efﬁcacy for
montelukast to treat BOS. We hypothesized that FAM
(Fluticasone propionate (440 mcg inhaled bid, provided by
GlaxoSmithKline), Azithromycin (250 mg 3x/week), and
Montelukast (10mg QD, provided by Merck) for up to 6
months, with brief steroid pulse could avert progression of
new-onset BOS and tested this in a phase II, single-arm, open
label, multicenter study (NCT01307462).
Results: Thirty-six patients from 10 institutions were
enrolled within 6 months of BOS diagnosis (NIH modiﬁed
criteria: FEV1<75% predicted, FEV1/VC <0.7, and >10% FEV1
decline from pre-HSCT, absence of infection). Themedian age
was 57 years (range 23-72), 47% were females, with
moderate obstruction (median FEV1 46%; FEV1/FVC 0.5) at
enrollment. The primary endpoint was treatment success,
deﬁned as < 10% FEV1 decline at 3 months, with 60%
treatment success seen in historical controls (published
data). FAM was well tolerated with only 1 grade 4 SAE
possibly related to FAM (infection), and no patient stopped
FAM prior to 3 months. 3 month results: Eighty-three
percent (n¼30/36) had treatment success (vs. 60% in
historical controls, p¼0.004) at 3 months; 5 lacked
pulmonary function tests (PFTs), and 1 had decline.
Assuming patients without PFTs at 3 months were treatment
failures, 36% (n¼13/36) had increased FEV1 by 5% or more,
and 33% (n¼12/36) had less than 5% decline in FEV1. Steroid
exposure was reduced signiﬁcantly from a median of 0.65
mg/kg/day at enrollment to 0.31 mg/kg/day at 3 months in
evaluable patients, with only 19% receiving added
immunosuppression during that period (associated with
<20% of successes). Based on NIH calculated overall cGVHD
response, 19% had a CR or PR, while 22% had stable disease at
3 months. Patient-reported outcomes (n¼24) were better
from baseline to 3 months for SF-36 social functioning score
(p¼0.03) and mental component score (p¼0.02), FACT
emotional well-being (p¼0.03), and Lee symptom scores in
lung (p¼0.01), skin (p¼0.03), mouth (p¼0.03), and overall
summary score (p¼0.001). Six minute walk test improved by
a median of 127 feet (p¼0.02). 6 month results: 10 patients
could not be evaluated at 6 months: 1 died, 1 withdrew, 5 did
not undergo PFTs and 3 were on study < 6 months; 20/26
